Cargando…

FOXL1 overexpression is associated with poor outcome in patients with glioma

Gliomas are the most common primary tumors in adult central nervous system and result in disappointing survival outcomes. FOXL1, as a transcription factor, plays an important role in regulating the expression of genes involved in cell metabolism, proliferation and differentiation. In this study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ainian, Zhong, Lingling, Lv, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540307/
https://www.ncbi.nlm.nih.gov/pubmed/31289550
http://dx.doi.org/10.3892/ol.2019.10351
_version_ 1783422586087014400
author Chen, Ainian
Zhong, Lingling
Lv, Jia
author_facet Chen, Ainian
Zhong, Lingling
Lv, Jia
author_sort Chen, Ainian
collection PubMed
description Gliomas are the most common primary tumors in adult central nervous system and result in disappointing survival outcomes. FOXL1, as a transcription factor, plays an important role in regulating the expression of genes involved in cell metabolism, proliferation and differentiation. In this study, we investigated the relationship between FOXL1 expression and prognosis of patients with glioma. We selected 611 glioma patients from The Cancer Genome Atlas (TCGA) database and 132 glioma patients from Huai'an First People's Hospital (PFHH). The prognostic values of FOXL1 in glioma were analyzed in both cohorts. In TCGA cohort, the median (10.2389) was used as the cut-off value of FOXL1 mRNA levels in tumor tissue. Kaplan-Meier analysis showed that higher WHO glioma grade (P<0.001) and expression of FOXL1 (P<0.001) were associated with worse overall survival (OS). The univariate Cox regression model revealed that age (P<0.001), WHO grade (P<0.001), histological type (P<0.001) and FOXL1 expression (P<0.001) were associated with prognosis of glioma patients. In PFHH cohort, expression of FOXL1 in tumor cells was detected by immunohistochemistry (IHC) staining based on a tissue microarray (TMA) sample. Kaplan-Meier analysis also showed that WHO glioma grade (P<0.001) and expression of FOXL1 (P=0.012) were associated with OS in glioma patients. The univariate Cox regression showed that WHO grade (P=0.001), histological type (P<0.001) and FOXL1 expression (P=0.013) were associated with prognosis of glioma patients. In both cohorts Kaplan-Meier subgroup analyses showed FOXL expression correlated with OS in high WHO grade subgroup, while low grade subgroup showed no such correlation. This study showed that higher expression of FOXL1 is associated with poor OS of glioma patients in TCGA and PFHH cohorts. Especially, FOXL1 overexpression is associated with worse outcomes in high WHO grade subgroup. Our findings suggest that FOXL1 expression is a candidate predictor of clinical outcome in glioma patients and may act as an effective molecular marker for immunotherapeutic strategies of glioma patients in clinical practice.
format Online
Article
Text
id pubmed-6540307
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-65403072019-07-09 FOXL1 overexpression is associated with poor outcome in patients with glioma Chen, Ainian Zhong, Lingling Lv, Jia Oncol Lett Articles Gliomas are the most common primary tumors in adult central nervous system and result in disappointing survival outcomes. FOXL1, as a transcription factor, plays an important role in regulating the expression of genes involved in cell metabolism, proliferation and differentiation. In this study, we investigated the relationship between FOXL1 expression and prognosis of patients with glioma. We selected 611 glioma patients from The Cancer Genome Atlas (TCGA) database and 132 glioma patients from Huai'an First People's Hospital (PFHH). The prognostic values of FOXL1 in glioma were analyzed in both cohorts. In TCGA cohort, the median (10.2389) was used as the cut-off value of FOXL1 mRNA levels in tumor tissue. Kaplan-Meier analysis showed that higher WHO glioma grade (P<0.001) and expression of FOXL1 (P<0.001) were associated with worse overall survival (OS). The univariate Cox regression model revealed that age (P<0.001), WHO grade (P<0.001), histological type (P<0.001) and FOXL1 expression (P<0.001) were associated with prognosis of glioma patients. In PFHH cohort, expression of FOXL1 in tumor cells was detected by immunohistochemistry (IHC) staining based on a tissue microarray (TMA) sample. Kaplan-Meier analysis also showed that WHO glioma grade (P<0.001) and expression of FOXL1 (P=0.012) were associated with OS in glioma patients. The univariate Cox regression showed that WHO grade (P=0.001), histological type (P<0.001) and FOXL1 expression (P=0.013) were associated with prognosis of glioma patients. In both cohorts Kaplan-Meier subgroup analyses showed FOXL expression correlated with OS in high WHO grade subgroup, while low grade subgroup showed no such correlation. This study showed that higher expression of FOXL1 is associated with poor OS of glioma patients in TCGA and PFHH cohorts. Especially, FOXL1 overexpression is associated with worse outcomes in high WHO grade subgroup. Our findings suggest that FOXL1 expression is a candidate predictor of clinical outcome in glioma patients and may act as an effective molecular marker for immunotherapeutic strategies of glioma patients in clinical practice. D.A. Spandidos 2019-07 2019-05-13 /pmc/articles/PMC6540307/ /pubmed/31289550 http://dx.doi.org/10.3892/ol.2019.10351 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Chen, Ainian
Zhong, Lingling
Lv, Jia
FOXL1 overexpression is associated with poor outcome in patients with glioma
title FOXL1 overexpression is associated with poor outcome in patients with glioma
title_full FOXL1 overexpression is associated with poor outcome in patients with glioma
title_fullStr FOXL1 overexpression is associated with poor outcome in patients with glioma
title_full_unstemmed FOXL1 overexpression is associated with poor outcome in patients with glioma
title_short FOXL1 overexpression is associated with poor outcome in patients with glioma
title_sort foxl1 overexpression is associated with poor outcome in patients with glioma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540307/
https://www.ncbi.nlm.nih.gov/pubmed/31289550
http://dx.doi.org/10.3892/ol.2019.10351
work_keys_str_mv AT chenainian foxl1overexpressionisassociatedwithpooroutcomeinpatientswithglioma
AT zhonglingling foxl1overexpressionisassociatedwithpooroutcomeinpatientswithglioma
AT lvjia foxl1overexpressionisassociatedwithpooroutcomeinpatientswithglioma